Telomir Pharmaceuticals (TELO) News Today $4.20 -0.24 (-5.41%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Telomir Pharmaceuticals (NASDAQ:TELO) versus Bionomics (NASDAQ:BNOX) Head to Head ReviewNovember 18 at 1:51 AM | americanbankingnews.comTelomir Pharmaceuticals (NASDAQ:TELO) Trading Up 3.8% - Still a Buy?Telomir Pharmaceuticals (NASDAQ:TELO) Shares Up 3.8% - Should You Buy?November 12, 2024 | marketbeat.comTelomir Pharmaceuticals, Inc. (NASDAQ:TELO) Sees Large Growth in Short InterestTelomir Pharmaceuticals, Inc. (NASDAQ:TELO - Get Free Report) was the target of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 672,400 shares, a growth of 410.9% from the September 15th total of 131,600 shares. Based on an average daily trading volume, of 122,200 shares, the short-interest ratio is currently 5.5 days. Approximately 4.0% of the company's shares are sold short.October 10, 2024 | marketbeat.comTelomir Pharmaceuticals, Inc. (NASDAQ:TELO) Sees Large Increase in Short InterestTelomir Pharmaceuticals, Inc. (NASDAQ:TELO - Get Free Report) was the target of a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 161,600 shares, an increase of 26.1% from the August 15th total of 128,200 shares. Approximately 1.0% of the shares of the company are short sold. Based on an average daily volume of 76,500 shares, the short-interest ratio is currently 2.1 days.September 14, 2024 | marketbeat.comTelomir Pharmaceuticals (NASDAQ:TELO) Trading Up 2.2%Telomir Pharmaceuticals (NASDAQ:TELO) Trading 2.2% HigherSeptember 14, 2024 | marketbeat.comTelomir Pharmaceuticals Inc (TELO)September 1, 2024 | investing.comTelomir Pharmaceuticals (NASDAQ:TELO) Trading Up 3.2%Telomir Pharmaceuticals (NASDAQ:TELO) Trading 3.2% HigherAugust 22, 2024 | marketbeat.comTELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q2 2024August 14, 2024 | investorplace.comTelomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher ChapmanAugust 12, 2024 | globenewswire.comTelomir Pharmaceuticals, Inc.'s Lock-Up Period Will Expire on August 7th (NASDAQ:TELO)Telomir Pharmaceuticals' (NASDAQ:TELO - Get Free Report) lock-up period will expire on Wednesday, August 7th. Telomir Pharmaceuticals had issued 1,000,000 shares in its IPO on February 9th. The total size of the offering was $7,000,000 based on an initial share price of $7.00. After the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.July 31, 2024 | marketbeat.comTelomir Pharmaceuticals (NASDAQ:TELO) Trading Up 15.5%Telomir Pharmaceuticals (NASDAQ:TELO) Trading Up 15.5%July 6, 2024 | marketbeat.comTelomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap IndexesJuly 2, 2024 | markets.businessinsider.comTelomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting PanelJune 17, 2024 | globenewswire.comTelomir Pharmaceuticals (NASDAQ:TELO) Trading 2.2% Higher Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Up 2.2%June 14, 2024 | marketbeat.comTelomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1May 30, 2024 | globenewswire.comTELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q1 2024May 14, 2024 | investorplace.comTrading was temporarily halted for "TELO" at 11:04 AM with a stated reason of "LULD pause."April 22, 2024 | marketbeat.comTelomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.April 16, 2024 | globenewswire.comTelomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024April 2, 2024 | globenewswire.comUPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in CaninesMarch 29, 2024 | globenewswire.comTelomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in CaninesMarch 26, 2024 | globenewswire.comTelomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26thMarch 22, 2024 | globenewswire.comTelomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate's Potential in DNA Age Reversal ScienceMarch 14, 2024 | globenewswire.comTelomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore ConferenceMarch 7, 2024 | globenewswire.comTelomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore ConferenceMarch 7, 2024 | globenewswire.comMichael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age ReversalMarch 5, 2024 | globenewswire.comTrading was temporarily halted for "TELO" at 10:02 AM with a stated reason of "LULD pause."February 20, 2024 | marketbeat.comTrading was temporarily halted for "TELO" at 03:02 PM with a stated reason of "LULD pause."February 14, 2024 | marketbeat.comTrading was temporarily halted for "TELO" at 03:02 PM with a stated reason of "LULD pause."February 14, 2024 | marketbeat.comTrading was temporarily halted for "TELO" at 02:02 PM with a stated reason of "LULD pause."February 14, 2024 | marketbeat.comTrading was temporarily halted for "TELO" at 02:02 PM with a stated reason of "LULD pause."February 14, 2024 | marketbeat.comTrading was temporarily halted for "TELO" at 01:02 PM with a stated reason of "LULD pause."February 14, 2024 | marketbeat.comTrading was temporarily halted for "TELO" at 01:02 PM with a stated reason of "LULD pause." Trading set to resume at 01:02 PM. February 12, 2024 | marketbeat.comTrading was temporarily halted for "TELO" at 11:02 AM with a stated reason of "LULD pause."February 9, 2024 | marketbeat.comTrading was temporarily halted for "TELO" at 11:02 AM with a stated reason of "LULD pause."February 9, 2024 | marketbeat.comTrading was temporarily halted for "TELO" at 10:02 AM with a stated reason of "LULD pause."February 9, 2024 | marketbeat.com Get Telomir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump said you could learn something from this man (Ad)Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. TELO Media Mentions By Week TELO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TELO News Sentiment▼0.690.45▲Average Medical News Sentiment TELO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TELO Articles This Week▼10▲TELO Articles Average Week Get Telomir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Monte Rosa Therapeutics News PureTech Health News Terns Pharmaceuticals News Mereo BioPharma Group News Arcturus Therapeutics News Y-mAbs Therapeutics News Zevra Therapeutics News ProKidney News Esperion Therapeutics News REGENXBIO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TELO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
